Savara (NASDAQ:SVRA) announced its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14, Fidelity Earnings reports.
NASDAQ SVRA traded down $0.07 during midday trading on Friday, hitting $0.84. The company had a trading volume of 581,000 shares, compared to its average volume of 394,757. Savara has a fifty-two week low of $0.82 and a fifty-two week high of $11.96. The stock has a market cap of $40.28 million, a price-to-earnings ratio of -0.65 and a beta of 0.10. The company has a quick ratio of 12.61, a current ratio of 12.61 and a debt-to-equity ratio of 0.22. The firm has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $4.38.
Several research analysts recently commented on SVRA shares. Evercore ISI set a $17.00 target price on shares of Savara and gave the stock a “buy” rating in a report on Monday, August 12th. ValuEngine upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Friday. Finally, LADENBURG THALM/SH SH reiterated a “hold” rating and issued a $1.00 target price on shares of Savara in a report on Thursday, October 3rd. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Savara has an average rating of “Hold” and an average target price of $9.09.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: What is quantitative easing?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.